Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma Gets Flexible As Licensing Activity Heats Up

Executive Summary

Many pharmaceutical manufacturers are adopting new approaches to licensing deals as competition to fill pipelines intensifies and firms scramble to gain rights to innovative compounds and technologies

You may also be interested in...



Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec

AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19

Licensing An Adjunct To In-House R&D, Not A Substitute – AstraZeneca Exec

AstraZeneca views licensing and acquisitions as an add-on to, rather than a replacement for, internal research & development, Exec Director-Development John Patterson said Sept. 19

Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”

GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses

Related Content

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel